CONSTITUENT REPORT
Carvone
Carvone is a well-known monoterpene ketone that helps define the aroma of spearmint, caraway, dill, and other carvone-rich oils in the AromaForge archive. Public evidence is strong for identity, flavor/fragrance use, human metabolism, and enantiomer-specific odor context, while the bioactivity literature is much broader but mostly preclinical. The current source-grounded picture supports describing carvone as a high-recognition aroma constituent with antimicrobial, anti-inflammatory, and sensory-receptor research signals, while avoiding medical claims and noting that even JECFA's current flavoring specifications for the separated d- and l-forms remain tentative pending completion of safety evaluation.
Chemical identity and composition
PubChem lists the parent carvone record as CID 7439 with formula C10H14O. Carvone is routinely discussed as two enantiomers with different sensory associations: JECFA's d-carvone entry describes a caraway-like odor, while the l-carvone entry describes a spearmint-like odor. Archive oil files already reflect that split, with spearmint records pointing to the levorotatory form and caraway or dill records using the generic parent constituent.
Aroma and practical use
- Use the recorded minty, caraway-like, sweet, spicy, herbal, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2022 systematic review identified ninety-one experimental carvone studies across ten pharmacological-activity categories, but concluded that many included studies had uncertain risk of bias and that more mechanism and safety work is needed.
A 2022 systematic review identified ninety-one experimental carvone studies across ten pharmacological-activity categories, but concluded that many included studies had uncertain risk of bias and that more mechanism and safety work is needed.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2013 cell study reported that (-)-carvone acted as a TRPV1 agonist in dorsal root ganglion neurons and recombinant human TRPV1-expressing cells, with an EC50 around 1.3 mM in the HEK293 model.
A 2013 cell study reported that (-)-carvone acted as a TRPV1 agonist in dorsal root ganglion neurons and recombinant human TRPV1-expressing cells, with an EC50 around 1.3 mM in the HEK293 model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2001 human metabolism study found both S-(+)- and R-(-)-carvone were metabolized mainly to dihydrocarvonic acid, carvonic acid, and uroterpenolone, with no major qualitative difference between the two enantiomers.
A 2001 human metabolism study found both S-(+)- and R-(-)-carvone were metabolized mainly to dihydrocarvonic acid, carvonic acid, and uroterpenolone, with no major qualitative difference between the two enantiomers.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
A North American Contact Dermatitis Group analysis reported positive patch tests to carvone in 188 of 24,124 tested patients, with 73.3% of the positive reactions judged currently relevant and common exposure sources including personal care products and food.
A North American Contact Dermatitis Group analysis reported positive patch tests to carvone in 188 of 24,124 tested patients, with 73.3% of the positive reactions judged currently relevant and common exposure sources including personal care products and food.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedJECFA's current online flavoring specifications list both d-carvone and l-carvone as tentative and state that safety evaluation is not completed.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Patch-test literature indicates carvone can function as a contact allergen, particularly in mint-flavored oral-care exposure contexts, even if prevalence is relatively low.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
No direct public citation is attached to this entry.
Most efficacy-style carvone literature remains in vitro or animal-based, so archive copy should not convert those findings into therapeutic claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
LimoneneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Limonene report →PulegoneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Pulegone report →How the effects were investigated
TRPV1 agonism for (-)-carvone
A PubMed-indexed cell study reported that (-)-carvone increased intracellular calcium in dorsal root ganglion neurons and TRPV1-expressing HEK293 cells, with blockade by capsazepine and ruthenium red supporting TRPV1-channel activation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
membrane_disruption_and_ultrastructural_antimicrobial_effects
The 2021 review summarizes antimicrobial studies that attribute carvone activity partly to cell-membrane disruption and ultrastructural changes rather than to one single validated human target.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
human_oxidative_and_reductive_metabolism
Human metabolism studies found carvone is converted mainly to dihydrocarvonic acid, carvonic acid, and uroterpenolone, with minor carveol and dihydrocarveol formation and little evidence of major enantiomeric differences in overall metabolite identity.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- The archive-level parent record covers carvone broadly, but the literature and regulatory specifications often separate d- and l-carvone; users should not assume every result applies identically to both enantiomers.
- Much of the benefit-oriented carvone literature remains preclinical and heterogeneous in quality.
- A constituent-specific modern dermal-limit standard for generic carvone was not verified in this pass.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.